![American Society of Clinical Oncology American Society of Clinical Oncology](https://54d4f314-8f94-415c-acb7-fd0a6332f070.s3.amazonaws.com/403/403__asco-logo-lg__274272709.png?X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIAU2BE4PNFKE2WZV7V%2F20240908%2Fus-east-1%2Fs3%2Faws4_request&X-Amz-Date=20240908T001846Z&X-Amz-SignedHeaders=host&X-Amz-Expires=86400&X-Amz-Signature=a9c2c5d6377eca717a50d4d61cb4b993b0c09165b2280fd34b2835d7c9d2ef7c)
Adjuvant Therapy for Stage III Colon Cancer
Publication Date: April 15, 2019
Key Points
Key Points
In 2018, approximately 97,000 people living in the United States will be diagnosed with colon cancer. Of these patients, just less than one-third will have stage III disease, characterized by spread to regional lymph nodes and absence of distant metastases.
The primary treatment option for patients with stage III colon cancer is resection with curative intent, however recurrence rates can be as high as 50–80% with surgery alone.
Adjuvant chemotherapy is recommended to improve overall survival for patients who have a high risk of recurrence.
The primary treatment option for patients with stage III colon cancer is resection with curative intent, however recurrence rates can be as high as 50–80% with surgery alone.
Adjuvant chemotherapy is recommended to improve overall survival for patients who have a high risk of recurrence.
Treatment
...reatmen...
...or patients with stage III resected co...
...with high risk (T4 and/or N2) stage III re...
...r patients with low risk (T1, T2, or...
...ision-making approach should be used for duratio...
...ry of Key Evidence from the Internation...
...subgroup analyses by risk of recurr...
...specified subgroup analysis by type of oxaliplat...